Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
about
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection(4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus EntryRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionHepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.New perspectives for preventing hepatitis C virus liver graft infection.Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.Clinical development of hepatitis C virus host-targeting agents.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match.Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.RACK1 controls IRES-mediated translation of viruses.Evaluation of antiviral drug synergy in an infectious HCV system.Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry.Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesTargeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.Variation analysis of E1 and E2 in HCV subtypes.A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry.Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models.[Locked outside: cure of chronic hepatitis C using an entry inhibitor].Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.
P2860
Q26779128-5A3C7D45-C6DA-4F84-8C46-95947C8F571CQ27468939-EF06691E-9D64-491F-B03B-1EC446BB5EFCQ28545971-C0F18CCA-57F4-4A75-9DB3-A0C4D75D9109Q30386551-6A780BB3-E18B-4D14-9FB7-8E4A44A07764Q33648339-90FCE492-EA1B-4E22-A949-94EFBF87E9D0Q35602911-8317C14B-898D-4E10-A523-0CF5D5EA15EBQ35828072-AC81F875-6B32-4EDC-9AE8-A3AEEA4EF95FQ36926843-C2AA3A8E-3F14-4586-B2C0-71B07AD14572Q37015805-382A017E-F2E0-4FEE-86A1-A687F3E42704Q37073281-34E7BF95-E14F-452E-A20E-DE394E7A09D1Q37662513-6D43E17F-6FEB-4673-B659-D34430FCC560Q38515906-E63F3A6C-5F64-4F34-A6C5-99C864FE66BAQ38602682-64267EFA-E78C-4547-80E1-92B76DB4ED76Q38818422-E131C8C1-0882-4A60-8C07-C86812DF579DQ38850319-4089DC50-EFFE-4B1F-9C9E-BE3CDDF70F76Q38938490-DC208E62-C6E2-45D7-BBC9-5CCA609AE455Q39871877-1EF6D384-D9D1-41D2-81C9-2B7336721923Q40113286-99594F8F-52E3-43F3-90ED-9664D9F61E5DQ40150500-6F780D64-5183-4443-911F-75E0A0D9B166Q40198772-6B8AC17B-BED0-48AB-80D4-FADFAC095EE5Q40271516-51E8F02A-EC77-49F0-8371-A06176ECB506Q40994676-49E58BF6-B781-4413-93FF-6D166CA9A659Q41033867-7AD9C5EA-1C21-4B02-94B3-52BEC94FCB28Q41096636-011C7E55-CC1F-443C-B2D2-6DDDB13E2D57Q41981846-17A3CD2E-49F1-460A-B803-F66DD2ED6495Q44781142-8D2FDFC8-3FA9-468E-A7C3-D7C718824625Q45325612-C9E10EE6-2E3D-490F-99BD-54A6FF54FAA1Q47350013-2E98A370-DBA5-4AC8-87FC-64DA694554B6Q52332712-58FE8195-51C0-4E2B-B469-8F6B1EF48B04Q54702553-CC20FDD5-FE33-43F5-AFBE-ABA8CEED3AC2Q55280981-73353C29-C2DD-4421-80E8-74A86A73FF65Q55282191-682D02CC-92EC-426A-8DC9-8116D5D81250
P2860
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@ast
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@en
type
label
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@ast
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@en
prefLabel
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@ast
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@en
P2093
P2860
P50
P1433
P1476
Synergy of entry inhibitors wi ...... and treatment of hepatitis C.
@en
P2093
Christine Thumann
Eric Robinet
François Habersetzer
Isabel Fofana
Michel Doffoël
Mickaël Schaeffer
Mirjam B Zeisel
Nicolas Meyer
Roxane Alles
Thomas F Baumert
P2860
P304
P356
10.1136/GUTJNL-2013-306155
P407
P577
2014-05-21T00:00:00Z